Caliway Biopharmaceuticals stock gets China trial clearance

Caliway Biopharmaceuticals said on November 6 that Chinese regulators authorized the CBL-0102 clinical study for CBL-514 to proceed. The announcement gives the clinical-stage company a new development milestone in China as it advances its injectable candidate for localized subcutaneous fat reduction.

The Caliway Biopharmaceuticals announcement said the Center for Drug Evaluation of China's National Medical Products Administration cleared the study ahead of the company's anticipated timeline. The authorization covers clinical development, not commercial approval of CBL-514.

Study Targets Asian Development

CBL-0102 is expected to begin enrolling participants in December 2026 and is planned for completion in the second quarter of 2027. Caliway expects clinical data shortly afterward, although those dates are company forecasts rather than completed milestones.

The randomized, open-label, single-dose, parallel-design study is expected to include about 30 healthy subjects at two Chinese sites. It will examine ethnicity sensitivity, pharmacokinetics, safety and tolerability across different dose levels. The results could support future clinical development and regulatory submissions in China and other Asian markets.

Clinical Program Remains Unapproved

CBL-514 is being developed for localized subcutaneous fat reduction and remains an investigational candidate. The China study adds a regional pharmacokinetic and safety component to the broader program, while pivotal efficacy results and any future regulatory decision remain ahead.

Investors can follow the TA-35 market environment for developments across Taiwan-linked biotechnology and healthcare shares.

More company updates are available in More news and analyses on Caliway Biopharmaceuticals stock.